Wedbush reissued their outperform rating on shares of TESARO Inc (NASDAQ:TSRO) in a research report report published on Wednesday morning. The firm currently has a $164.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $200.00.
Several other research analysts have also commented on the stock. Morgan Stanley started coverage on shares of TESARO in a report on Friday, January 13th. They issued an overweight rating and a $172.00 price target on the stock. Cowen and Company cut their price target on shares of TESARO from $155.00 to $145.00 and set a market perform rating on the stock in a report on Wednesday, March 15th. Bank of America Corp raised their price target on shares of TESARO from $149.26 to $165.00 in a report on Thursday, January 19th. Leerink Swann restated an outperform rating and issued a $152.00 price target (up previously from $115.00) on shares of TESARO in a report on Monday, January 9th. Finally, Citigroup Inc restated a sell rating and issued a $238.00 price target on shares of TESARO in a report on Monday, January 30th. One analyst has rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $160.27.
TESARO (NASDAQ:TSRO) opened at 152.05 on Wednesday. The stock has a 50 day moving average of $173.60 and a 200 day moving average of $135.82. TESARO has a one year low of $36.68 and a one year high of $192.94. The firm’s market cap is $8.15 billion.
In other news, VP Edward C. English sold 10,000 shares of TESARO stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $178.06, for a total transaction of $1,780,600.00. Following the sale, the vice president now owns 5,396 shares in the company, valued at $960,811.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Mary Lynne Hedley sold 3,927 shares of TESARO stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $177.61, for a total transaction of $697,474.47. Following the sale, the chief operating officer now owns 10,000 shares in the company, valued at approximately $1,776,100. The disclosure for this sale can be found here. Insiders have sold 15,793 shares of company stock worth $2,801,638 in the last quarter. Insiders own 40.50% of the company’s stock.
Several hedge funds have recently bought and sold shares of TSRO. IFP Advisors Inc raised its stake in TESARO by 109.6% in the second quarter. IFP Advisors Inc now owns 4,208 shares of the biopharmaceutical company’s stock worth $354,000 after buying an additional 2,200 shares in the last quarter. Cupps Capital Management LLC purchased a new stake in TESARO during the third quarter worth about $1,725,000. Fox Run Management L.L.C. purchased a new stake in TESARO during the third quarter worth about $381,000. CenturyLink Investment Management Co purchased a new stake in TESARO during the third quarter worth about $172,000. Finally, Moody Aldrich Partners LLC purchased a new stake in TESARO during the third quarter worth about $773,000. Institutional investors own 98.48% of the company’s stock.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.